ImmunoSABR is a six-year research project funded by the European Commission’s Horizon 2020: the EU Framework for Programme for Research and Innovation. It is a phase II trial to test if the combination of Stereotactic Body Radiation Therapy and L19-IL2 immuno-oncology therapy improves the progression free survival in people with limited metastatic non-small cell lung cancer.

This study is not yet open for participant recruitment. The research project will run from January 2017 to December 2022.


ImmunoSABR Objectives

The ImmunoSABR clinical trial is trying to find a better way to treat metastatic cancer. In this randomised open label phase II clinical trial, stereotactic ablative radiotherapy (SABR) will be combined with L19-IL2 immuno-oncology therapy in people with limited metastatic non small cell lung cancer (clinicaltrials.gov no. NCT02735850). ImmunoSABR will also use cancer biomarkers to develop a way to predict which people will most benefit from this novel treatment strategy.

ECPC’s Role

The European Cancer Patient Coalition is part of the consortium to represent the voice of the European cancer patient. ECPC will organise a dedicated patient consultation session to discuss the ImmunoSABR trial, providing a platform for panel discussions with patients regarding clinical trial design. ECPC will also give input into the development of the informed consent forms and the patient information brochure. In addition, the European Cancer Patient Coalition is participating in the Work Package 6, responsible for ‘Consortium management, dissemination and exploitation’. This entails conveying information about the ImmunoSABR trial to our own network, all other relevant European patient organisations, and the public. Finally, a dissemination activity will be organised within the European Parliament.

ImmunoSABR WPs

Contact Points

ECPCIsabelle Manneh-Vangramberen ECPC Head of Health & Research Programmes

Project CoordinatorsProf. Philippe Lambin and Natascha DominguezMaastricht University

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research team in Maastricht, The Netherlands.


EU Flag

ImmunoSABR is funded by Horizon 2020: the EU Framework for Programme for research and InnovationProject N° 733008.

Project Website